AstraZeneca: CHMP recommends Imfinzi and Lynparza

(CercleFinance.com) - AstraZeneca announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval in the EU of Imfinzi (durvalumab) and Lynparza (olaparib) to treat certain patients with primary or recurrent advanced endometrial cancer.


Imfinzi + chemotherapy as first-line treatment, followed by Lynparza and Imfinzi has been recommended for patients with mismatch repair disease (pMMR).

Imfinzi + chemotherapy followed by Imfinzi alone has been recommended for patients with mismatch repair deficient disease (dMMR).

The CHMP relies on an analysis from a phase III trial published in the Journal of Clinical Oncology in October 2023.

This analysis showed a 43% reduction in the risk of disease progression or death for pMMR patients in the Lynparza and Imfinzip arm compared with the control arm, and a 58% reduction for dMMR patients in the Imfinzi arm compared with the control arm.


Copyright (c) 2024 CercleFinance.com. All rights reserved.